June 30, 2022
Ms Elaine Teo is the Director, Aged and Ancillary Services Regulation, and Regulatory Transformation in the Health Regulation Group, Ministry of Health, Singapore.
Trained as a pharmacist, Ms Teo has been with the Singapore Ministry of Health (MOH) since 2003 where she was instrumental in the establishment of the Optometrists and Opticians Board, the Allied Health Professions Council (AHPC), and the Agency for Care Effectiveness (ACE). At AHPC, she served as the inaugural registrar where she led the successful state licensure and professional regulation for key allied health professions. As Head of the policy and planning team in ACE, she facilitated international collaborations for capacity building, and orchestrated the launch of ACE’s first guidances to positive reception, securing sustained cooperation and resources for ACE’s new initiatives and subsequent expansion.
Currently, as a director in the Health Regulation Group, she oversees the regulation of the aged care and ancillary services sectors to assure patient safety; and champions regulatory transformation through regulatory sandboxes, use of analytics, consumer engagement and education initiatives for more agile regulatory responses to new risks emerging in the rapidly evolving healthcare landscape.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system